The Ratio of Plasma Amyloid-β 1-42 over Serum Albumin Can Be a Novel Biomarker Signature for Diagnosing End-Stage Renal Disease-Associated Cognitive Impairment

Apr 8

Written By Yiran Gan

2024.10.29

Hou Yi-Choua, Chueh Ti-I, Lu Kuo-Cheng, Liu Yi-Chien, Chen Tso-Hsiao, Liu Shing-Hwa, Chen Ruei-Ming

Journal of Alzheimer's Disease, vol. 97, no. 3, pp. 1393-1405, 2024

Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial